Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.
Saved in:
| Title: | Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. |
|---|---|
| Authors: | Strohl WR; BiStro Biotech Consulting, LLC, Bridgewater, NJ, 08807, USA. wrstrohl@gmail.com., Ku Z; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Sciences Center, Houston, TX, USA., An Z; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Sciences Center, Houston, TX, USA., Carroll SF; IGM Biosciences, Inc., Mountainview, CA, USA., Keyt BA; IGM Biosciences, Inc., Mountainview, CA, USA., Strohl LM; Biomedscapes, Bridgewater, NJ, 08807, USA. |
| Source: | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2022 May; Vol. 36 (3), pp. 231-323. Date of Electronic Publication: 2022 Apr 27. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9705305 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-190X (Electronic) Linking ISSN: 11738804 NLM ISO Abbreviation: BioDrugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
